Philips(US:PHG) 智通财经网·2026-02-10 07:21Core Viewpoint - Philips reported better-than-expected financial performance for Q4 2025, with sales growth driven by multiple business segments, indicating a strong operational recovery despite ongoing tariff pressures [1][3]. Financial Performance - Q4 2025 sales reached €5.1 billion, a 1% increase year-over-year, surpassing market expectations [1][2]. - Comparable sales growth was 7%, exceeding analyst consensus of 4.9%, supported by growth in all major business segments: 4% in diagnostics and treatment, 7% in connected care, and 14% in personal health [1][2]. - Adjusted EBITA for Q4 was €770 million, above the consensus estimate of €672 million, with an adjusted EBITA margin of 15.1%, up 160 basis points from the previous year [1][2]. - Net income for Q4 was €397 million, a significant recovery from a net loss of €333 million in the same quarter last year [1][2]. Cost Management - The company achieved cost savings of €800 million in 2025, which helped offset tariff costs estimated between €150 million and €200 million [2][4]. Future Outlook - Philips has revised its 2026 comparable sales growth forecast to 3% to 4.5%, down from approximately 4.5%, reflecting ongoing tariff pressures and weak performance in the Chinese market [3]. - The adjusted EBITA margin for 2026 is expected to be between 12.5% and 13% [3]. - The company has set medium-term financial targets for 2026-2028, aiming for a mid-single-digit CAGR in comparable sales and an adjusted EBITA margin of around 15% by 2028, with projected cumulative free cash flow of €4.5 billion to €5 billion [4].